https://orcid.org/0000-0003-1039-8166
References
- Prialt. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration; 2006. cited 2019 Sept 27. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021060s003lbl.pdf
- Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20:133–154.
- Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20:155–176.
- Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20:96–132.
- Prialt (ziconotide) [package insert]. Lake Forest (IL): TerSera Therapeutics; 2019.
- Deer TR, Rauck RL, Kim P, et al. Effectiveness and safety of intrathecal ziconotide: interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2017;18(2):230–238.
- Webster L. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide: a review of the literature. Pain Med. 2015;16(7):1265–1277.
- Staats P, Yearwood T, Charapata S, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63–70.
- Wallace M, Charapata S, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9(2):75–86.
- Rauck R, Wallace M, Leong M, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31(5):393–406.
- Pope JE, Deer TR. Intrathecal ziconotide in the treatment of failed back surgery syndrome. Pain Med News Spec Ed. 2014; 79–80.
- Kapural L, Lokey K, Leong MS, et al. Intrathecal ziconotide for complex regional pain syndrome: seven case reports. Pain Pract. 2009;9(4):296–303.
- Stanton-Hicks M, Kapural L. An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide. J Pain Symptom Manage. 2006;32(6):509–511.
- Pope JE, Deer TR, Bruel BM, et al. Clinical uses of intrathecal therapy and its placement in the pain care algorithm. Pain Pract. 2016;16(8):1092–1106.
- Anand P, O’Neil A, Lin E, et al. Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers. Sci Rep. 2015;5:12497.
- Burton AW, Deer TR, Wallace MS, et al. Considerations and methodology for trialing ziconotide. Pain Physician. 2010;13:23–33.
- Ahmed S, Martin N, Chang Y. Patient selection and trial methods for intraspinal drug delivery for chronic pain: a national survey. Neuromodulation. 2005;8(2):112–120.
- McDowell GC, Pope JE. Intrathecal ziconotide: dosing and administration strategies in patients with refractory chronic pain. Neuromodulation. 2016;19(5):522–532.
- Maeyaert J, Buchser E, Van Buyten J, et al. Patient-controlled analgesia in intrathecal therapy for chronic pain: safety and effective operation of the model 8831 personal therapy manager with a pre-implanted synchromed infusion system. Neuromodulation. 2003;6(3):133–141.
- McDowell GC Use of the personal therapy manager with Prialt® (ziconotide) for patient‐controlled analgesia: a case series highlighting techniques and outcomes. Presented at the 14th Annual Meeting of the North American Neuromodulation Society; Las Vegas (NV); December 2–52010. [cited 2019 Sept 9]. Available from: http://www.slideserve.com/uri/use-of-the-personal-therapy-manager-with-prialt-ziconotide-intrathecal-infusion-for-patient-controlled-analgesia-case
- Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation. 2015;18:414–420.
- Saulino M, Kim P, Shaw E. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014;7:627–638.
- Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5:521–534.